Do analysts prefer TSE or EVGN?

Trinseo presently has a consensus price target of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher probable upside, equities research analysts plainly believe Trinseo is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinseo 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is TSE or EVGN more profitable?

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Trinseo -13.15% N/A -11.72% Evogene -638.12% -158.82% -80.37%

Do analysts recommend SNES or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senestech 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is SNES or EVGN more profitable?

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Senestech -304.22% -67.60% -49.21% Evogene -638.12% -158.82% -80.37%

Do analysts rate GURE or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gulf Resources 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is GURE or EVGN more profitable?

Gulf Resources has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Gulf Resources' return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Gulf Resources N/A N/A N/A Evogene -638.12% -158.82% -80.37%

Do analysts prefer EVGN or ORGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Origin Materials 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVGN or ORGN more profitable?

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -638.12% -158.82% -80.37% Origin Materials -1,742.04% -120.66% -99.50%

Evogene (EVGN) Competitors

$0.43 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.43 +0.00 (+1.00%)

As of 07/2/2026 07:00 PM Eastern

Compare

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

Should you buy Evogene stock or one of its competitors? MarketBeat compares Evogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evogene include Carisma Therapeutics (CARM), Trinseo (TSE), Senestech (SNES), Gulf Resources (GURE), and Origin Materials (ORGN).

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.02	-$60.48M	$0.73	0.01
Evogene	$3.85M	0.97	-$8.48M	-$1.39	N/A

Carisma Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 16,293.44%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Carisma Therapeutics has a beta of -9.86, meaning that its stock price is 1,086% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-158.82%	-80.37%

Summary

Carisma Therapeutics beats Evogene on 9 of the 14 factors compared between the two stocks.

How does Evogene compare to Trinseo?

Trinseo (NYSE:TSE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Trinseo presently has a consensus price target of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher probable upside, equities research analysts plainly believe Trinseo is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinseo	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

82.7% of Trinseo shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 4.5% of Trinseo shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinseo	$3.13B	0.00	-$348.50M	-$11.55	N/A
Evogene	$3.85M	0.97	-$8.48M	-$1.39	N/A

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinseo	-13.15%	N/A	-11.72%
Evogene	-638.12%	-158.82%	-80.37%

In the previous week, Trinseo's average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Trinseo	Neutral
Evogene	Neutral

Trinseo has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market. Comparatively, Evogene has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

Summary

Trinseo beats Evogene on 8 of the 14 factors compared between the two stocks.

How does Evogene compare to Senestech?

Senestech (NASDAQ:SNES) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Senestech had 4 more articles in the media than Evogene. MarketBeat recorded 4 mentions for Senestech and 0 mentions for Evogene. Senestech's average media sentiment score of 0.97 beat Evogene's score of 0.00 indicating that Senestech is being referred to more favorably in the media.

Company	Overall Sentiment
Senestech	Positive
Evogene	Neutral

5.2% of Senestech shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 2.2% of Senestech shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senestech	-304.22%	-67.60%	-49.21%
Evogene	-638.12%	-158.82%	-80.37%

Senestech has higher earnings, but lower revenue than Evogene. Senestech is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$2.22M	3.56	-$6.38M	-$1.89	N/A
Evogene	$3.85M	0.97	-$8.48M	-$1.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Senestech has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

Summary

Senestech and Evogene tied by winning 7 of the 14 factors compared between the two stocks.

How does Evogene compare to Gulf Resources?

Gulf Resources (NASDAQ:GURE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Gulf Resources has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market. Comparatively, Evogene has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

In the previous week, Gulf Resources' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score.

Company	Overall Sentiment
Gulf Resources	Neutral
Evogene	Neutral

Gulf Resources has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Gulf Resources' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gulf Resources	N/A	N/A	N/A
Evogene	-638.12%	-158.82%	-80.37%

Evogene has lower revenue, but higher earnings than Gulf Resources. Evogene is trading at a lower price-to-earnings ratio than Gulf Resources, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gulf Resources	$20.72M	0.27	-$58.94M	-$48.05	N/A
Evogene	$3.85M	0.97	-$8.48M	-$1.39	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gulf Resources	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

3.3% of Gulf Resources shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 3.2% of Gulf Resources shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Evogene beats Gulf Resources on 8 of the 13 factors compared between the two stocks.

How does Evogene compare to Origin Materials?

Evogene (NASDAQ:EVGN) and Origin Materials (NASDAQ:ORGN) are both small-cap chemicals companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Evogene has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Origin Materials has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, Origin Materials had 1 more articles in the media than Evogene. MarketBeat recorded 1 mentions for Origin Materials and 0 mentions for Evogene. Origin Materials' average media sentiment score of 0.87 beat Evogene's score of 0.00 indicating that Origin Materials is being referred to more favorably in the news media.

Company	Overall Sentiment
Evogene	Neutral
Origin Materials	Positive

Evogene has a net margin of -638.12% compared to Origin Materials' net margin of -1,742.04%. Origin Materials' return on equity of -120.66% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-158.82%	-80.37%
Origin Materials	-1,742.04%	-120.66%	-99.50%

10.4% of Evogene shares are held by institutional investors. Comparatively, 29.9% of Origin Materials shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 2.8% of Origin Materials shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Origin Materials	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has higher earnings, but lower revenue than Origin Materials. Evogene is trading at a lower price-to-earnings ratio than Origin Materials, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	0.97	-$8.48M	-$1.39	N/A
Origin Materials	$18.92M	0.28	-$249.70M	-$47.83	N/A

Summary

Evogene beats Origin Materials on 9 of the 15 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.75M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-0.31	21.61	28.02	24.70
Price / Sales	0.97	343.35	538.99	99.06
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.31	8.66	10.96	6.46
Net Income	-$8.48M	$23.81M	$3.57B	$337.01M
7 Day Performance	9.34%	3.39%	2.12%	1.69%
1 Month Performance	-30.58%	10.81%	5.25%	3.81%
1 Year Performance	-68.40%	62.61%	33.29%	23.90%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	0.6483 of 5 stars	$0.43 flat	N/A	-68.4%	$3.75M	$3.85M	N/A	140	Gap Down
CARM Carisma Therapeutics	2.6555 of 5 stars	$0.01 +1.7%	$1.00 +16,566.7%	-98.5%	$251K	$10.77M	0.01	20
TSE Trinseo	N/A	$0.23 flat	$1.00 +334.8%	N/A	$8.10M	$3.13B	N/A	2,950
SNES Senestech	2.5038 of 5 stars	$1.49 flat	N/A	-70.9%	$7.90M	$2.22M	N/A	30	News Coverage High Trading Volume
GURE Gulf Resources	0.7373 of 5 stars	$3.65 -6.9%	N/A	-46.8%	$6.04M	$7.66M	N/A	420	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Trinseo?

Summary

How does Evogene compare to Senestech?

Summary

How does Evogene compare to Gulf Resources?

Summary

How does Evogene compare to Origin Materials?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, TSE, SNES, GURE, and ORGN

How does Evogene compare to Carisma Therapeutics?

Does the media prefer CARM or EVGN?

Do insiders and institutionals have more ownership in CARM or EVGN?

Which has better valuation and earnings, CARM or EVGN?

Do analysts prefer CARM or EVGN?

Which has more risk and volatility, CARM or EVGN?

Is CARM or EVGN more profitable?

Summary

How does Evogene compare to Trinseo?

Do analysts prefer TSE or EVGN?

Do institutionals & insiders have more ownership in TSE or EVGN?

Which has preferable earnings & valuation, TSE or EVGN?

Is TSE or EVGN more profitable?

Does the media favor TSE or EVGN?

Which has more risk & volatility, TSE or EVGN?

Summary

How does Evogene compare to Senestech?

Does the media prefer SNES or EVGN?

Do institutionals & insiders have more ownership in SNES or EVGN?

Is SNES or EVGN more profitable?

Which has stronger earnings & valuation, SNES or EVGN?

Do analysts recommend SNES or EVGN?

Which has more risk & volatility, SNES or EVGN?

Summary

How does Evogene compare to Gulf Resources?

Which has more risk and volatility, GURE or EVGN?

Does the media prefer GURE or EVGN?

Is GURE or EVGN more profitable?

Which has higher earnings and valuation, GURE or EVGN?

Do analysts rate GURE or EVGN?

Do institutionals & insiders hold more shares of GURE or EVGN?

Summary

How does Evogene compare to Origin Materials?

Which has more volatility and risk, EVGN or ORGN?

Does the media favor EVGN or ORGN?

Is EVGN or ORGN more profitable?

Do insiders and institutionals hold more shares of EVGN or ORGN?

Do analysts prefer EVGN or ORGN?

Which has better valuation and earnings, EVGN or ORGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools